Liesbeth became involved with Sutura’s exciting technology platform in 2020. Together with Edwin Wagena, she initially supported the founders of the Company by preparing a drug development plan for Sutura’s first product. Liesbeth intensified her collaboration and involvement with Sutura in 2021 as head of CMC and is now responsible for R&D and CMC.

Since 2007, Liesbeth has been responsible for the development and manufacturing of innovative therapies, including advanced therapy medicinal products (ATMPs), and orphan drugs. Prior to joining Sutura, Liesbeth was director of Manufacturing at Kiadis, fellow at Novartis, and VP R&D and Manufacturing at Ixaka (formerly known as Rexgenero). Liesbeth holds a PhD in molecular biology from Amsterdam University in The Netherlands.